Used in research and development for bone-related diseases, particularly in conditions involving impaired bone formation such as osteoporosis and multiple myeloma. Targets DKK1 (Dickkopf-related protein 1), a natural inhibitor of the Wnt signaling pathway, which plays a critical role in bone remodeling. By neutralizing DKK1, this antibody helps restore Wnt pathway activity, promoting osteoblast activity and new bone formation. Investigated for therapeutic potential to increase bone mineral density and reduce skeletal complications in cancer patients with bone metastases. Also serves as a reference standard in immunoassays and preclinical studies evaluating anti-DKK1 agents.